Check-Cap Ltd. (NASDAQ:CHEK) Sees Large Decrease in Short Interest

Check-Cap Ltd. (NASDAQ:CHEK) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 131,100 shares, a drop of 78.2% from the March 31st total of 600,000 shares. Approximately 3.0% of the shares of the stock are short sold. Based on an average daily volume of 251,300 shares, the days-to-cover ratio is presently 0.5 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of Check-Cap in a research report on Tuesday. They issued a “sell” rating on the stock.

Check-Cap Price Performance

CHEK traded up $0.02 on Friday, reaching $2.29. 22,716 shares of the company’s stock were exchanged, compared to its average volume of 206,415. The stock has a market cap of $13.37 million, a PE ratio of -0.76 and a beta of 0.28. Check-Cap has a twelve month low of $1.27 and a twelve month high of $4.63. The stock’s fifty day moving average price is $2.26 and its 200-day moving average price is $2.56.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.